Pharmacological profile of a novel, non-TZD PPARgamma agonist (Q38323080)

2 September 2017

title

Pharmacological profile of a novel, non-TZD PPARgamma agonist (English)

1 reference

2 September 2017

Chen X

1

1 reference

2 September 2017

Osborne MC

2

1 reference

2 September 2017

Rybczynski PJ

3

1 reference

2 September 2017

Zeck R

4

1 reference

2 September 2017

Yang M

5

1 reference

2 September 2017

Xu J

6

1 reference

2 September 2017

Zhou L

7

1 reference

2 September 2017

Cryan E

8

1 reference

2 September 2017

Tang Y

9

1 reference

2 September 2017

Demarest KT

10

1 reference

2 September 2017

publication date

1 September 2005

1 reference

Diabetes, Obesity and Metabolism

2 September 2017

published in

1 reference

2 September 2017

volume

7

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

536-546

1 reference

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Identification of two mPPAR related receptors and evidence for the existence of five subfamily members

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Characterization of adenosine A1 receptors in human proximal tubule epithelial (HK-2) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Muscle-specific Pparg deletion causes insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

A futile metabolic cycle activated in adipocytes by antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00425.X

10.1111/J.1463-1326.2004.00425.X

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference